Skip to main content

Table 5 Analysis of the correlation between risk stratification of GPC3 and PIVKA-II and the clinical features of HCC

From: Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models

Clinical features

Number

GPC3-highrisk

(> 0.124 ng/mL)

OR (95%CI)

P value

PIVKA-II-highrisk

(> 274mAU/mL)

OR (95%CI)

P value

Age, n(%)

       

 ≤ 60 years

52

26 (50.00%)

1.167 (0.540–2.519)

0.695

32 (61.54%)

2.779 (1.256–6.149)

0.011

 > 60 years

52

24 (46.15%)

19 (36.54%)

Gender, n(%)

       

 Male

96

45 (46.88%)

0.529 (0.120–2.341)

0.395

50 (52.08%)

7.609 (0.901–64.232)

0.031

 Female

8

5 (62.50%)

1 (12.5%)

Cirrhosis, n(%)

       

 Yes

70

33 (47.14%)

0.892 (0.393–2.025)

0.784

36 (51.43%)

1.341 (0.589–3.055)

0.484

 No

34

17 (50.00%)

15 (44.11%)

Hepatitis B virus, n(%)

       

 Yes

92

43 (46.74%)

0.627 (0.185–2.120)

0.450

47 (51.09%)

2.089 (0.588–7.423)

0.247

 No

12

7 (58.33%)

4 (33.33%)

PVT, n(%)

       

 Yes

45

24 (53.33%)

1.451 (0.665–3.162)

0.349

29 (64.44%)

3.048 (1.360–6.831)

0.006

 No

59

26 (44.07%)

22 (37.29%)

Tumor size, n(%)

       

 < 3 cm

29

12 (41.38%)

2.511 (2.036–2.986)

0.034

4 (13.79%)

3.144 (2.720–3.568)

0.000

 3–5 cm

42

16 (38.10%)

22 (52.38%)

 > 5 cm

33

22 (66.67%)

25 (75.76%)

Daughter nodule, n(%)

       

 Yes

45

26 (57.78%)

0.501 (0.228–1.101)

0.084

29 (64.44%)

0.328 (0.146–0.735)

0.006

 No

59

24 (40.68%)

22 (37.29%)

Intrahepatic metastasis, n(%)

       

 Yes

34

19 (55.88%)

1.594 (0.698–3.636)

0.267

25 (73.53%)

4.701 (1.905–11.598)

0.000

 No

70

31 (44.29%)

26 (37.14%)

Distant metastasis, n(%)

       

 Yes

18

14 (77.78%)

4.861 (1.477–15.994)

0.006

10 (55.56%)

1.372 (0.494–3.810)

0.543

 No

86

36 (41.86%)

41 (47.67%)

Ascites, n(%)

       

 Yes

35

19 (54.29%)

1.456 (0.643–3.295)

0.367

23 (65.71%)

2.807 (1.203–6.549)

0.015

 No

69

31 (44.93%)

28 (40.58%)

ALB, n(%)

       

 40–55 g/L

35

15 (42.86%)

0.729 (0.321–1.653)

0.448

15 (42.86%)

0.688 (0.303–1.560)

0.369

 < 40 g/L

69

35 (50.72%)

36 (52.17%)

TBIL, n(%)

       

 5–21µmol/L

74

35 (47.30%)

0.897 (0.384–2.097)

0.803

37 (50.00%)

1.143 (0.489–2.673)

0.758

 > 21µmol/L

30

15 (50.00%)

14 (46.67%)

  1. CHB, Chronic Hepatitis B. PVT, portal vein thrombosis. ALB, albumin. TBIL, total bilirubin
  2. Categorical variables were compared by the chi-square test or Fisher’s exact test and P < 0.05 was statistically significant
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us